Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of HBM9161 in Healthy Chinese Volunteers
NCT03971916Phase 1Completed
- Sponsor
- Harbour BioMed
- Start
- Jun 2019
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of batoclimab in myasthenia gravis (MG), Graves' ophthalmopathy (TED), Neuromyelitis Optica Spectrum Disorder (NMOSD) and 2 more (4 arms), sponsored by Harbour BioMed. Primary endpoint: The number of subjects with drug-related Adverse Events at 85 days. Started Jun 2019; status: completed.
02
Drugs
batoclimab
03
Conditions
myasthenia gravis (MG)Graves' ophthalmopathy (TED)Neuromyelitis Optica Spectrum Disorder (NMOSD)immune thrombocytopenia (ITP)autoimmune diseases
Beyond the preview
Go deeper on NCT03971916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971916.